Skip to main content
. Author manuscript; available in PMC: 2013 Sep 30.
Published in final edited form as: Expert Opin Emerg Drugs. 2012 Nov 19;17(4):469–492. doi: 10.1517/14728214.2012.744393

Figure 3. Schematic diagram to depict the next generation of preventive HPV vaccines based on HPV capsid proteins (L1 and/or L2).

Figure 3

A. Cervarix composed of HPV-16 and HPV-18 VLPs. B. Gardasil composed of HPV-6, HPV-11, HPV-16 and HPV-18 VLPs. C. Multivalent VLP vaccines composed of HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52 and HPV-58 VLPs (V503 Merck). D. L1 capsomer vaccine. E. Chimeric L1-L2 VLP vaccine with L2 on the surface. F. L2 peptide vaccine. G. Concatenated L2 peptide vaccine. H. L2 peptides displayed on the surface of bacteriophage VLP.